Abstract
The adoption of decentralized (DCT) study methods including e-consent, eCOA, telehealth visits, home health and direct to patient (DTP) study supplies have been accelerated in the SARS-COV-2 pandemic to maintain research continuity. However, DCT approaches have not been universally accepted by regulatory authorities (RAs) and ethics committees (ECs). The aim is to summarize intelligence on the adoption of DCT study methods in order to characterize the current global regulatory landscape.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
